ClinicalTrials.gg

Program

domvanalimab

Also written as “Domvanalimab” and “Domvanalimab (DOM)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Adenocarcinoma Of Esophagus · Squamous Cell Carcinoma of Head and Neck, led by 3 companies.

Furthest: phase 3, since Aug 12, 202210 company-led studies, 6 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences55 open or runningphase 3since Aug 12, 2022Apr 26, 2018Mar 2027phase 2 · NCT06727565
Arcus Biosciences40 open or runningphase 3since Oct 3, 2022Jul 26, 2018none ahead
AstraZeneca11 open or runningphase 3since Jan 11, 2022Jan 11, 2022none ahead

Also a collaborator on its studies: Otsuka and Merck KGaA, Darmstadt, Germany.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 26, 2018First study: phase 2 study in Metastatic Urothelial CancerNew to Gilead SciencesGilead Sciences · NCT03547973 · 502 enrolled · United States, France, Germany and more
  2. Jul 26, 2018Arcus Biosciences's first study: phase 1 study in Solid Tumor, Unspecified, AdultNew to Arcus BiosciencesArcus Biosciences · NCT03628677 · 75 enrolled · United States, Australia
  3. Jan 29, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungArcus Biosciences · NCT04736173 · 169 enrolled · United States, Hong Kong, Malaysia and more
  4. Jan 11, 2022AstraZeneca's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to AstraZenecaAstraZeneca · NCT05211895 · 791 enrolled · United States, Belgium, Brazil and more
  5. Apr 8, 2022Phase 2 study in Adenocarcinoma Of EsophagusArcus Biosciences · NCT05329766 · 332 enrolled · United States, Canada, Chile and more
  6. Aug 12, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungGilead Sciences · NCT05502237 · 1,021 enrolled · United States, Argentina, Austria and more
  7. Oct 3, 2022Phase 3 study in Adenocarcinoma Of EsophagusArcus Biosciences · NCT05568095 · 1,040 enrolled · United States, Argentina, Australia and more
  8. Nov 21, 2022Phase 2 study in Lung NeoplasmsGilead Sciences · NCT05633667 · 192 enrolled · United States, Brazil, Hong Kong and more
  9. Dec 9, 2022Phase 2 study in Advanced Non-Small Cell Lung CancerGilead Sciences · NCT05676931 · 400 enrolled · United States, Australia, France and more
  10. Dec 9, 2024Phase 2 study in Squamous Cell Carcinoma of Head and NeckGilead Sciences · NCT06727565 · 39 enrolled · United States, Australia, China and more

Ahead

  1. Mar 2027Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckGilead Sciences · NCT06727565
  2. Dec 2027Primary completion: phase 2 study in Advanced Non-Small Cell Lung CancerGilead Sciences · NCT05676931
  3. Jun 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungGilead Sciences · NCT05502237
  4. Sep 2029Primary completion: phase 2 study in Lung NeoplasmsGilead Sciences · NCT05633667

TargetBeta

TIGIT →read by rule
“A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), ”NCIt, by rule
“T-cell immunoreceptor with Ig and ITIM domains inhibitor”ChEMBL 37, by rule

Other programs on TIGIT

ProgramCompanyFurthest phaseStudies
rilvegostomigAstraZenecaphase 324
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
BC008-1Arulesichuan-luzhou-buchang-biopharmaceutical-co-ltdphase 12

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06727565Squamous Cell Carcinoma of Head and Neck · United States, Australia, China and more2Active, not recruitingGilead SciencesMar 202739
NCT05676931Advanced Non-Small Cell Lung Cancer · United States, Australia, France and more2Active, not recruitingGilead SciencesDec 2027400
NCT05633667Lung Neoplasms · United States, Brazil, Hong Kong and more2Active, not recruitingGilead SciencesSep 2029192
NCT05568095Adenocarcinoma Of Esophagus · United States, Argentina, Australia and more3CompletedArcus BiosciencesAug 28, 20261,040
NCT05502237Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more3Active, not recruitingGilead SciencesJun 20281,021
NCT05329766Adenocarcinoma Of Esophagus · United States, Canada, Chile and more2CompletedArcus BiosciencesSep 7, 2026332
NCT05211895Carcinoma, Non-Small-Cell Lung · United States, Belgium, Brazil and more3Active, not recruitingAstraZenecaAug 10, 2026791
NCT04736173Carcinoma, Non-Small-Cell Lung · United States, Hong Kong, Malaysia and more2CompletedArcus BiosciencesSep 17, 2026169
NCT03628677Solid Tumor, Unspecified, Adult · United States, Australia1CompletedArcus BiosciencesJan 23, 202575
NCT03547973Metastatic Urothelial Cancer · United States, France, Germany and more2Active, not recruitingGilead SciencesApr 2030502

How it is read

Names in the registry

  • “Domvanalimab”, 9 entries
  • “Domvanalimab (DOM)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.